New male contraceptive succeeds in first month of testing
Currently, male contraceptives are limited only to condoms and vasectomy, unlike women who may choose different ways to avoid pregnancy. Researchers at the University of Washington in the United States have developed a male contraceptive, and the first clinical trials are promising.
The new male pill has been named as dimethandrolone undecanoate, or DMAU. Like the female oral contraceptives, DMAU has a combination of hormones to inhibit sperm production.
In a presentation at the annual conference of the Society of Endocrinology in March, the scientists showed data on research done with 100 volunteers between the ages of 18 and 50, with 83 completing all stages of the experiment.
Three different doses of the compound were tested for analysis. Participants were divided into groups of five, who received the medication or placebos. They took the pills daily over 28 days along with food intake, a requirement for the effectiveness of the substance.
When tested at the highest dose of 400 milligrams, the results indicated low levels of all hormones needed for sperm production. Low levels of testosterone can lead to loss of sexual desire and fatigue, but few volunteers had these effects.
However, all men who took the medication gained weight and dropped HDL, the good cholesterol levels. However, the researchers believe that these effects are not a cause for concern, since kidney and liver functions have remained normal.
New, more complex analyzes will be needed to check for undesirable medium- and long-term effects, especially, how long fertility takes to be fully restored with treatment discontinuation.
New more complex analyzes will be needed to check for undesirable medium- and long-term effects - and especially how long fertility takes to be restored with discontinuation of treatment.
The mouth can be a great access for the entrance of bacteria. And if the hygiene of the place is not performed correctly, these microorganisms create a bacterial plaque that lodges in the teeth, near the gingiva, to cause a picture of inflammation: gingivitis. The problem has been increasingly present in dentistry and calls attention of health professionals.
On September 20, 2016, the Official Gazette of the Union has published the approval of the drug rivastigmine patch transdermal (Exelon® Patch) in the Unified Health System (SUS). The remedy is a new treatment option for patients with Alzheimer's disease, for treating disorders of memory and dementia.